Mra (tocilizumab) (DrugBank: Tocilizumab)
2 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
46 | Malignant rheumatoid arthritis | 4 |
107 | Juvenile idiopathic arthritis [Systemic juvenile idiopathic arthritis (~Mar 2018)] | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00144534 (ClinicalTrials.gov) | June 2004 | 2/9/2005 | Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP | An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA213JP | Rheumatoid Arthritis | Drug: MRA (Tocilizumab) | Chugai Pharmaceutical | NULL | Completed | 20 Years | 75 Years | Both | 115 | Phase 3 | NULL |
2 | NCT00144508 (ClinicalTrials.gov) | March 2003 | 2/9/2005 | Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA) | An Open-Label, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RA | Rheumatoid Arthritis | Drug: MRA (Tocilizumab);Other: current treatment | Chugai Pharmaceutical | NULL | Completed | 20 Years | N/A | Both | 306 | Phase 3 | NULL |
3 | JPRN-JapicCTI-050016 | 02/09/2005 | A controlled, randomized trial of MRA monotherapy in patients with rheumatoid arthritis(RA) | A controlled, randomized trial of MRA monotherapy in patients with rheumatoid arthritis(RA) | RA | Intervention name : MRA (tocilizumab) Dosage And administration of the intervention : Intravenous infusion | Chugai Pharmaceutical Co., Ltd. | NULL | 20 | Phase 3 | NULL | |||||
4 | JPRN-JapicCTI-050018 | 02/09/2005 | Double-blind, parallel-group, controlled Phase 3 study of MRA in rheumatoid arthritis(RA) | Double-blind, parallel-group, controlled Phase 3 study of MRA in rheumatoid arthritis(RA) | RA | Intervention name : MRA (tocilizumab) Dosage And administration of the intervention : Intravenous infusion | Chugai Pharmaceutical Co., Ltd. | NULL | 20 | 74 | Phase 3 | NULL |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-JapicCTI-050017 | 02/09/2005 | Phase 3 clinical study of MRA in patients with systemic juvenile idiopathic arthritis (sJIA) | Phase 3 clinical study of MRA in patients with systemic juvenile idiopathic arthritis (sJIA) | sJIA | Intervention name : MRA (tocilizumab) Dosage And administration of the intervention : Intravenous infusion | Chugai Pharmaceutical Co., Ltd. | NULL | 2 | 19 | Phase 3 | NULL |